Ajay K. Singh, MBBS, FRCP, MBA
Articles by Ajay K. Singh, MBBS, FRCP, MBA
Ajay Singh talks dialytrauma—harmful effects of dialysis in patients with AKI moving from inpatient to outpatient care.
Ajay Singh discusses the state of rare kidney disease research.
Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.
Dr. Ajay Singh discusses the reasons why medical students and residents are not choosing to pursue careers in nephrology.
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
Editor's Note:
...
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.